Login to Your Account

Financings Roundup

AVI: $30M Public Offering; DMD Drug Heads to Phase II

By Jennifer Boggs

Monday, April 4, 2011
AVI BioPharma Inc., which recently vowed to speed up work on Duchenne's muscular dystrophy (DMD) candidate AVI-4658, is padding its coffers with a $30 million public offering.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription